Search

The purpose of this article is to analyse the strategy of managerial professionalization through educational reform as it has been attempted in Britain during the course of the 1980s. This strategy - whatever its internal contradictions and inherent weaknesses - is located within the longer-term historical context in which British management has developed. In turn, this brief historical analysis is complemented by an assessment of the feasibility of the strategy of professionalization in relation to some of the most recent work carried out on the sociology of the professions/expert knowledge. Finally, we discuss the broader implications of this analysis for current debates concerning the reality of managerial work and management culture, as well as the pedagogical principles and practices thought most appropriate to the latter - that is, how managers ought to be educated and developed. [ABSTRACT FROM AUTHOR]

Investigates the deaths caused by primary angiosarcoma of the liver (ASL) from the period 1963 to 1973 in Great Britain. Submission of histological material to a panel of histopathologist; Occupational and residential histories for the cases agreed of ASL; Findings of a single case associated with exposure to vinyl chloride.

The article presents obituaries for several notable people in medicine including general practitioner Roointon Faridoon Boomla, pathologist Thomas Hargreaves, and paediatrician Geoffrey Peter McMullin.

Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo., Methods/design: ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale-Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study-Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group., Discussion: Alzheimer's disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer's treatment., Trial Registration: ClinicalTrials.gov, NCT01843075 . Registration 30 April 2013.